-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
As a common disease, gastric cancer has a poor overall prognosis.
As a common disease, gastric cancer has a poor overall prognosis.
Gastric adenocarcinoma is the main histological type of gastric cancer (>95%).
The treatment strategy of gastric adenocarcinoma generally adopts a multidisciplinary approach, in which surgical resection (gastrectomy) is the main treatment method, while patients with unresectable or metastatic disease usually adopt chemotherapy and targeted therapies.
Recent studies have shown that metformin, as a first-line drug for diabetes , can improve the prognosis of patients with colon cancer and prostate cancer.
Metformin diabetic colon cancer
Kaplan-Meier survival curve of metformin in the treatment of gastric adenocarcinoma
Kaplan-Meier survival curve of metformin in the treatment of gastric adenocarcinomaThe researchers assessed the relationship between the use of metformin before diagnosis of gastric adenocarcinoma and the disease-specific mortality and all-cause mortality through multivariate Cox risk regression analysis.
Comparison of cumulative mortality curves between metformin users and non-users
Comparison of cumulative mortality curves between metformin users and non-usersAll in all, the results of the study reveal that metformin can improve the survival rate of gastric adenocarcinoma patients with diabetes.
The results of the study revealed that metformin can improve the survival rate of gastric adenocarcinoma patients with diabetes.
org/10.
Leave a message here